DUPILUMAB VERSUS OMALIZUMAB IN TYPE-2-HIGH PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND COEXISTENT ASTHMA. // Annals of Allergy, Asthma & Immunology. – URL: https://www.sciencedirect.com/science/article/pii/S1081120626012998?dgcid=rss_sd_all
DUPILUMAB VERSUS OMALIZUMAB IN TYPE-2-HIGH PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND COEXISTENT ASTHMA. Annals of Allergy, Asthma & Immunology. https://www.sciencedirect.com/science/article/pii/S1081120626012998?dgcid=rss_sd_all
“DUPILUMAB VERSUS OMALIZUMAB IN TYPE-2-HIGH PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND COEXISTENT ASTHMA.” Annals of Allergy, Asthma & Immunology.
@article{article93173,
title = {DUPILUMAB VERSUS OMALIZUMAB IN TYPE-2-HIGH PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND COEXISTENT ASTHMA},
journal = {Annals of Allergy, Asthma \& Immunology},
url = {https://www.sciencedirect.com/science/article/pii/S1081120626012998?dgcid=rss_sd_all}
}